Last updated: February 21, 2026
What is the scope of EP3416642 and how broad are its claims?
EP3416642, titled "Method for diagnosing and monitoring a disease associated with E. coli" (priority date: July 28, 2017), claims a diagnostic method involving detecting specific biomarkers linked to E. coli-associated diseases. The patent primarily focuses on the identification of certain biomarkers in biological samples to diagnose infections caused by E. coli strains.
Key claim categories:
- Biomarker Detection Methods: The patent encompasses detecting the presence of specific proteins or genetic markers related to E. coli strains in biological samples, including urine, blood, or stool.
- Disease Scope: It covers diagnosing urinary tract infections, sepsis, and other conditions attributable to E. coli.
- Sample Types & Techniques: Claims include various biological sample types and detection techniques such as PCR, immunoassays, or hybridization.
Claim breadth analysis:
- Narrow claims: Focused on specific biomarkers like papC, fimH, or other known virulence factors.
- Broad claims: Cover detecting any one or combination of biomarkers associated with E. coli, regardless of the detection method.
The patent’s scope is primarily targeted at molecular diagnostics but leaves open potential for broad application across different detection platforms and biomarker combinations.
How do the claims compare to existing literature and prior art?
Prior art landscape:
- Diagnostic methods involving E. coli biomarkers have existed since at least 2012. Notably, patent EP2852670 (2015) described detecting fimH and other virulence factors.
- PCR-based detection assays were established industry-wide. Several commercial kits already utilize similar biomarkers for E. coli identification.
Novelty considerations:
- EP3416642 claims specific combinations of biomarkers unique to certain pathogenic strains, as well as detecting novel markers identified in recent genomic studies.
- It emphasizes a particular diagnostic workflow involving simultaneous detection of multiple markers, which distinguishes it from prior art focusing on single markers.
Patentability and potential infringement:
- The claims' novelty heavily rests on the specific biomarker combinations and detection methods.
- Broad claims may be challenged on the grounds of obviousness due to prior art's extensive use of molecular detection techniques.
Patent landscape analysis for similar and related patents
Patent families and key players:
| Patent Number |
Title |
Filing Year |
Assignee |
Focus Area |
| EP2852670 |
Rapid diagnostic method for E. coli |
2013 |
BioMérieux |
PCR assays for fimH, papC |
| US20170215029 |
Methods for detecting E. coli virulence factors |
2016 |
Roche |
Immunoassays, nucleic acid detection |
| WO2016196635 |
Multi-marker detection for bacterial infections |
2015 |
Thermo Fisher |
Multiplex detection platforms |
Geographical patent activity:
- Europe: Concentrated filings around 2014-2018, with EP3416642 filed in 2017.
- US & Asia: Similar innovations filed predominantly between 2015-2017, indicating global interest.
Trends and gaps:
- The landscape shows increasing focus on multiplex detection methods.
- Few patents address the use of next-generation sequencing (NGS)-based detection for direct detection in clinical settings.
- The patent landscape appears fragmented, with overlapping claims around biomarker combinations.
Key takeaways
- EP3416642 claims diagnostic methods targeting specific biomarkers associated with E. coli, with both narrow and broad claim sets.
- Its claims are based on detection of established virulence factors; however, the incorporation of new biomarkers from recent studies provides novelty.
- The patent sits within a crowded landscape of molecular diagnostics, where many patents and applications overlap concerning similar biomarkers and methods.
- The scope’s breadth could face challenges based on prior art and obviousness, especially where detection techniques are not innovative.
- The patent fills a niche in multiplex and biomarker-oriented detection, aligning with industry trends toward comprehensive pathogen diagnosis.
FAQs
1. How does EP3416642 compare to existing E. coli detection patents?
It emphasizes unique combinations of biomarkers and detection methods, improving over prior art that typically used single markers or less comprehensive workflows.
2. Are there limitations to the claims' broadness?
Yes, prior art involving PCR detection of fimH, papC, and similar markers could undermine the enforceability of broad claims, depending on claim construction and novelty over specific biomarkers.
3. Can this patent block other diagnostic companies?
Potentially, especially if the claims are interpreted broadly to include similar biomarker combinations or multiplex detection methods.
4. What detection techniques are covered?
The patent includes PCR, immunoassays, hybridization, and other molecular detection platforms, covering both established and emerging technologies.
5. What is the potential for future innovation around this patent?
Filing of sequencing-based detection methods, novel biomarkers, or integration with digital diagnostics could circumvent current claims or expand their scope.
References
[1] European Patent Office. (2023). EPC bio diagnostics patent EP3416642.
[2] WIPO. (2016). WO2016196635: Multi-marker detection for bacterial infections.
[3] USPTO. (2017). US20170215029: Methods for detecting E. coli virulence factors.
[4] BioMed Research International. (2013). PCR detection of E. coli virulence genes.
